(TLX) Talanx - Ratings and Ratios
Insurance, Reinsurance, Life, Property, Casualty
TLX EPS (Earnings per Share)
TLX Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.5% |
| Value at Risk 5%th | 36.8% |
| Relative Tail Risk | -8.54% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.42 |
| Alpha | 40.80 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.467 |
| Beta | 0.057 |
| Beta Downside | 0.186 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.96% |
| Mean DD | 4.00% |
| Median DD | 3.26% |
Description: TLX Talanx October 14, 2025
Talanx AG (XETRA: TLX) is a German-based insurer and reinsurer that operates globally across a broad spectrum of life, non-life and specialty lines, including motor, aviation, cyber, and parametric solutions, as well as bancassurance and asset-management activities.
Founded in 1903 and headquartered in Hanover, the group is a subsidiary of HDI Haftpflichtverband der Deutschen Industrie V.a.G. and is classified under the GICS “Multi-line Insurance” sub-industry.
Key financial indicators (2023, per the company’s annual report) show a combined ratio of 94.5% for the non-life segment, a net profit of €1.2 billion, and a Solvency II ratio of 197%, indicating strong capital adequacy. The return on equity (ROE) stood at roughly 11%, aligning with the European insurance sector average.
Sector drivers that materially affect Talanx’s outlook include persistently low interest-rate environments that compress investment yields, heightened climate-related loss exposure (especially in property lines), and accelerating digital transformation that is reshaping underwriting and claims processing.
Assumption: the KPI figures are taken from the 2023 audited results; any material changes in regulatory capital requirements or macro-economic conditions could materially alter these metrics.
For a deeper quantitative breakdown, the ValueRay platform offers a granular view of TLX’s valuation metrics and scenario analyses.
TLX Stock Overview
| Market Cap in USD | 32,652m |
| Sub-Industry | Multi-line Insurance |
| IPO / Inception | |
| Return 12m vs S&P 500 | 28.7% |
| Analyst Rating | - |
TLX Dividends
| Dividend Yield | 2.41% |
| Yield on Cost 5y | 10.29% |
| Yield CAGR 5y | 11.88% |
| Payout Consistency | 99.6% |
| Payout Ratio | 39.7% |
TLX Growth Ratios
| CAGR 3y | 42.28% |
| CAGR/Max DD Calmar Ratio | 2.65 |
| CAGR/Mean DD Pain Ratio | 10.57 |
| Current Volume | 185k |
| Average Volume | 113.4k |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (2.26b TTM) > 0 and > 6% of Revenue (6% = 1.47b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 0.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -1.22% (prev 8.02%; Δ -9.24pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 8.43b > Net Income 2.26b (YES >=105%, WARN >=100%) |
| Net Debt (2.53b) to EBITDA (5.12b) ratio: 0.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (258.2m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 21.32% (prev 91.26%; Δ -69.94pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 13.91% (prev 29.13%; Δ -15.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.90 (EBITDA TTM 5.12b / Interest Expense TTM 330.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.31
| (A) -0.00 = (Total Current Assets 1.22b - Total Current Liabilities 1.52b) / Total Assets 177.29b |
| (B) 0.06 = Retained Earnings (Balance) 10.97b / Total Assets 177.29b |
| (C) 0.01 = EBIT TTM 1.29b / Avg Total Assets 175.63b |
| (D) 0.06 = Book Value of Equity 10.17b / Total Liabilities 159.04b |
| Total Rating: 0.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.70
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield -10.04% = -5.0 |
| 3. FCF Margin 34.52% = 7.50 |
| 4. Debt/Equity 0.66 = 2.29 |
| 5. Debt/Ebitda 0.49 = 2.31 |
| 6. ROIC - WACC (= 1.20)% = 1.51 |
| 7. RoE 19.15% = 1.60 |
| 8. Rev. Trend -27.24% = -2.04 |
| 9. EPS Trend 70.85% = 3.54 |
What is the price of TLX shares?
Over the past week, the price has changed by +6.16%, over one month by -1.49%, over three months by -6.66% and over the past year by +47.51%.
Is Talanx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TLX is around 143.32 EUR . This means that TLX is currently undervalued and has a potential upside of +27.85% (Margin of Safety).
Is TLX a buy, sell or hold?
What are the forecasts/targets for the TLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 105.4 | -6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 155 | 38.2% |
TLX Fundamental Data Overview January 01, 1970
Market Cap EUR = 28.17b (28.17b EUR * 1.0 EUR.EUR)
P/E Trailing = 12.4686
P/E Forward = 12.0919
P/S = 0.6223
P/B = 2.4121
P/EG = 1.2721
Beta = 0.427
Revenue TTM = 24.42b EUR
EBIT TTM = 1.29b EUR
EBITDA TTM = 5.12b EUR
Long Term Debt = 7.84b EUR (from longTermDebt, last quarter)
Short Term Debt = 293.0m EUR (from shortTermDebt, last fiscal year)
Debt = 7.84b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.53b EUR (from netDebt column, last quarter)
Enterprise Value = -84.01b EUR (28.17b + Debt 7.84b - CCE 120.02b)
Interest Coverage Ratio = 3.90 (Ebit TTM 1.29b / Interest Expense TTM 330.0m)
FCF Yield = -10.04% (FCF TTM 8.43b / Enterprise Value -84.01b)
FCF Margin = 34.52% (FCF TTM 8.43b / Revenue TTM 24.42b)
Net Margin = 9.25% (Net Income TTM 2.26b / Revenue TTM 24.42b)
Gross Margin = 21.32% ((Revenue TTM 24.42b - Cost of Revenue TTM 19.22b) / Revenue TTM)
Gross Margin QoQ = 13.24% (prev 9.94%)
Tobins Q-Ratio = -0.47 (set to none) (Enterprise Value -84.01b / Total Assets 177.29b)
Interest Expense / Debt = 1.47% (Interest Expense 115.0m / Debt 7.84b)
Taxrate = 22.12% (338.0m / 1.53b)
NOPAT = 1.00b (EBIT 1.29b * (1 - 22.12%))
Current Ratio = 0.80 (Total Current Assets 1.22b / Total Current Liabilities 1.52b)
Debt / Equity = 0.66 (Debt 7.84b / totalStockholderEquity, last quarter 11.85b)
Debt / EBITDA = 0.49 (Net Debt 2.53b / EBITDA 5.12b)
Debt / FCF = 0.30 (Net Debt 2.53b / FCF TTM 8.43b)
Total Stockholder Equity = 11.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.27% (Net Income 2.26b / Total Assets 177.29b)
RoE = 19.15% (Net Income TTM 2.26b / Total Stockholder Equity 11.80b)
RoCE = 6.56% (EBIT 1.29b / Capital Employed (Equity 11.80b + L.T.Debt 7.84b))
RoIC = 6.33% (NOPAT 1.00b / Invested Capital 15.85b)
WACC = 5.12% (E(28.17b)/V(36.01b) * Re(6.23%) + D(7.84b)/V(36.01b) * Rd(1.47%) * (1-Tc(0.22)))
Discount Rate = 6.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 77.89% ; FCFE base≈8.11b ; Y1≈7.90b ; Y5≈7.95b
Fair Price DCF = 547.1 (DCF Value 141.27b / Shares Outstanding 258.2m; 5y FCF grow -3.72% → 3.0% )
EPS Correlation: 70.85 | EPS CAGR: 55.15% | SUE: -1.10 | # QB: 0
Revenue Correlation: -27.24 | Revenue CAGR: -0.55% | SUE: -0.03 | # QB: 0